Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INC424 dose-finding study in myelofibrosis with thrombocytopenia
NL-OMON39946Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ruxolitinib in myelofibrosis (MF), primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and 1 more (2 arms), sponsored by Novartis. Primary endpoint: Dose-limiting toxicity. Started Oct 2012; status: active, not recruiting.
02
Drugs
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on NL-OMON39946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39946.